Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec;8(6):408-13.
doi: 10.1159/000357534.

Genomic profiling in triple-negative breast cancer

Cornelia Liedtke  1 , Christof Bernemann  2 , Ludwig Kiesel  2 , Achim Rody  1
Affiliations
Review

Genomic profiling in triple-negative breast cancer

Cornelia Liedtke et al. Breast Care (Basel). 2013 Dec.

Abstract
in English, German

Triple-negative breast cancer (TNBC) is defined by a lack of hormone receptor expression as well as lack of overexpression/amplification of HER2/neu. Patients with TNBC show a significantly worse prognosis compared to patients with other breast cancer subtypes. TNBC, however, is a heterogeneous entity both with regard to clinical/pathological characteristics and molecular biology. This review summarizes the current data on TNBC with a particular focus on mutational and gene expression profiling and the association between TNBC and breast cancer stem cells.

Das tripelnegative Mammakarzinom (triple negative breast cancer, TNBC) ist definiert durch eine fehlende Hormonrezeptorexpression sowie eine fehlende Amplifikation/Überexpression des HER2/neu-Onkogens. Patientinnen mit einem TNBC zeigen eine signifikant schlechtere Prognose im Vergleich zu Patientinnen mit anderen Mammakarzinomsubtypen. Jedoch handelt es sich beim TNBC durchaus um eine heterogene Erkrankung sowohl im Hinblick auf klinische/pathologische Parameter als auch auf molekularbiologische Faktoren. In dieser Übersichtsarbeit fassen wir die aktuellen Daten zum TNBC zusammen mit einem speziellen Fokus einerseits auf die Ergebnisse von Mutations- und Genexpressionsanalysen, andererseits auf den Zusammenhang zwischen TNBC und Mammakarzinom-Stammzellen.

Keywords: Heterogeneity; RNA profiling; Triple negative breast cancer, subtypes; Whole genome sequencing.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of intrinsic and clinically/immunohistochemically defined breast cancer subtypes within TNBC and BLBC (based on [9]).
See this image and copyright information in PMC

References

    1. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer – current status and future directions. Ann Oncol. 2009;20:1913–1927. - PubMed
    1. Carey L, Winer E, Viale G, et al. Triple-negative breast cancer: Disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683–692. - PubMed
    1. Heitz F, Harter P, Lueck HJ, et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer. 2009;45:2792–2798. - PubMed
    1. Liedtke C, Hess KR, Karn T, et al. The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2013;138:591–599. - PubMed
    1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. - PubMed